According to filings with the U.S. Securities and Exchange Commission, Pharmazz is raising up to $3,500,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Pharmazz
Pharmazz, Inc. is an innovative biopharmaceutical company based in Willowbrook, Illinois, USA, focused on discovering, acquiring, developing, and commercializing novel therapeutics for critical care and hospital settings. Established in 2010 as a Delaware corporation, the company has expanded globally with subsidiaries in India, the UK, and Europe to support its development and commercialization activities. Pharmazz has built a strong market position around two first in class, late stage drug products, centhaquine and sovateltide, targeting large unmet needs such as hypovolemic shock and acute cerebral ischemic stroke, and has obtained marketing authorization for Lyfaquin (centhaquine) in India. Its pipeline spans multiple critical care indications, including acute cerebral ischemic stroke, hypoxic ischemic encephalopathy, Alzheimers disease, ARDS, septic shock, and other undisclosed indications, reflecting a strategic focus on life threatening conditions in intensive care. Supported by a seasoned management team and partnerships with major institutions and pharmaceutical companies, Pharmazz positions itself as a late stage, emerging global leader in critical care medicine, aiming to transform outcomes for critically ill patients through first in class therapies.

To learn more, visit https://www.pharmazz.com/
LinkedIn: https://www.linkedin.com/company/pharmazz

Contact:
Anil Gulati, Chief Executive Officer

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.